PlainRecalls
FDA Devices Moderate Class II Ongoing

ellacor System with Micro-Coring Technology-Indicated for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV. Model #: Gen 4

Reported: August 16, 2023 Initiated: June 23, 2023 #Z-2393-2023

Product Description

ellacor System with Micro-Coring Technology-Indicated for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV. Model #: Gen 4

Reason for Recall

Potential failure of a bearing adhesive joint that can occur due to an assembly issue of the X/Y stage of the handpiece. If a broken glue bond were to occur, it could cause an overlap of cores, potentially leading to prolonged healing and irregularities in patient skin texture post-treatment, and/or scarring

Details

Units Affected
127 systems
Distribution
Nationwide
Location
Woburn, MA

Frequently Asked Questions

What product was recalled?
ellacor System with Micro-Coring Technology-Indicated for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV. Model #: Gen 4. Recalled by Cytrellis Biosystems, Inc.. Units affected: 127 systems.
Why was this product recalled?
Potential failure of a bearing adhesive joint that can occur due to an assembly issue of the X/Y stage of the handpiece. If a broken glue bond were to occur, it could cause an overlap of cores, potentially leading to prolonged healing and irregularities in patient skin texture post-treatment, and/or scarring
Which agency issued this recall?
This recall was issued by the FDA Devices on August 16, 2023. Severity: Moderate. Recall number: Z-2393-2023.